HCA Healthcare (NYSE:HCA) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS

HCA Healthcare (NYSE:HCA) announced its quarterly earnings data on Friday. The company reported $6.22 earnings per share for the quarter, beating the consensus estimate of $6.03 by $0.19, RTT News reports. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same period in the previous year, the firm posted $5.90 earnings per share. HCA Healthcare updated its FY 2025 guidance to 24.050-25.850 EPS.

HCA Healthcare Stock Down 4.0 %

HCA Healthcare stock opened at $312.51 on Friday. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. The firm has a market capitalization of $79.16 billion, a price-to-earnings ratio of 14.03, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64. The firm’s fifty day moving average price is $314.10 and its two-hundred day moving average price is $352.64. HCA Healthcare has a 1-year low of $279.93 and a 1-year high of $417.14.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the transaction, the insider now owns 6,843 shares of the company’s stock, valued at approximately $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares in the company, valued at $18,445,700. The trade was a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

HCA has been the topic of a number of analyst reports. Raymond James downgraded shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a research note on Friday, November 22nd. Oppenheimer boosted their price objective on shares of HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a research report on Monday, October 28th. TD Cowen lowered their price target on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a report on Monday, October 28th. KeyCorp decreased their target price on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $392.00 price target on shares of HCA Healthcare in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $385.27.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.